JelloX Biotech Establishes US Research Base
In a significant move to advance oncology through technology, JelloX Biotech Inc., a pioneering Taiwan-based startup in cancer pathology, is setting up a state-of-the-art 3D cancer pathology lab within the renowned Discovery Oasis biotech hub located in Phoenix, Arizona.
The Discovery Oasis offers a vast 120-acre development strategically designed as a biotechnology corridor fostering collaboration aimed at developing groundbreaking solutions for some of humanity’s most intricate medical dilemmas. With a dedicated space of approximately 1,100 square feet, JelloX is poised to leverage its new facility to apply advanced technologies such as 3D imaging and artificial intelligence (AI) to the realm of cancer pathology.
Dr. Yen-Yin Lin, CEO of JelloX, remarked on the initiative: “Addressing medical challenges such as cancer necessitates collaborative efforts from various stakeholders to improve treatments and patient care. We are excited to establish our research base in the US, which will enable us to collaborate with other pioneering entities in our quest to combat cancer, while simultaneously contributing to the country’s leadership in biotech innovation.”
JelloX’s Breakthrough in 3D Pathology Technology
The revolutionary 3D pathology technology developed by JelloX has demonstrated significantly higher sensitivity in diagnosing and treating oncology cases. Traditional tissue sampling methods have limitations in providing comprehensive data about tumors. However, 3D pathology methods can detect previously classified “false negatives” and facilitate early cancer detection. This empowers healthcare providers to initiate treatment sooner and with greater precision.
“3D pathology provides, at minimum, 50 times more information than traditional 2D methods, offering pathologists a deep insight into a tumor’s biology,” Dr. Lin explained. “The strength of this diagnostic tool lies in its capacity to enable pathologists to stratify and personalize treatments, ensuring the right patients receive the appropriate therapy at the optimal time, thereby improving prognosis, enhancing quality of life, and enabling more patient-centered care.”
JelloX has engaged in fruitful research collaborations with major healthcare institutions in Japan and Taiwan, consistently demonstrating the merit of 3D pathology across diverse demographics and various cancer types, including colorectal cancer, esophageal cancer, and HER2 detection in breast cancer.
Expanding Possibilities Across Healthcare Stakeholders
The integration of JelloX’s 3D pathology technology holds transformative potential for multiple facets of the healthcare industry:
- For Physicians: This innovative diagnostic tool offers a more comprehensive patient data set. When combined with AI, it aids in reducing physician workloads.
- For Pharmaceutical Companies and Research Institutions: JelloX’s technology bolsters companion diagnostics (CDx) for drug utilization and serves as a critical tool for the development of new medications.
- For Healthcare Systems: The adoption of 3D pathology optimizes the allocation of medical resources and minimizes unnecessary financial expenditures and healthcare burdens.
The establishment of a research lab in the U.S. underscores JelloX’s commitment to advancing cancer pathology and demonstrates their determination to collaborate with global partners in delivering cutting-edge solutions for improved patient outcomes.
JelloX Biotech Inc. continues to chart a path of innovation from its base in Hsinchu, Taiwan, with a dedicated focus on enhancing cancer pathology through the fusion of 3D digital imaging and AI technology.
